- ------------------------------------------------------------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE
ACT OF 1934
Date of Report (Date of earliest event reported)
January 7, 2000 (December 20, 1999)
ABGENIX, INC.
-------------
(Exact name of registrant as specified in its charter)
Delaware
--------
(State or other jurisdiction of incorporation or organization)
000-24207 94-3248826
--------- ----------
Commission File Number (I.R.S. Employer Identification Number)
7601 Dumbarton Circle
Fremont, California 94555
-------------------------
(Address of principal executive offices)
(510) 608-6500
--------------
(Registrant's telephone number, including area code)
- ------------------------------------------------------------------------------
ABGENIX, INC.
FORM 8-K
JANUARY 7, 2000
ITEM 5. OTHER EVENTS
On December 20, 1999, Abgenix announced that it will become the sole
owner of the XenoMouse-TM- by acquiring all of the interest in the technology
owned by JT America Inc. The press release has been filed as an exhibit to
this Report on Form 8-K.
Pursuant to the requirements of the Securities Exchange Act of 1934,
as amended, the Registrant has duly caused this report to be signed on its
behalf by the undersigned hereunder duly authorized.
ABGENIX, INC.
Date: January 6, 1999
/s/ R. SCOTT GREER
---------------------------------------
R. Scott Greer
President and Chief Executive Officer
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
(c) EXHIBITS (in accordance with Item 601 of Regulation S-K)
99.1 Press Release of Abgenix regarding the sole ownership of
XenoMouse fully human antibody.
ABGENIX, INC.
Report on Form 8-K
dated January 7, 2000
INDEX TO EXHIBITS
EXHIBIT
NUMBER EXHIBIT NAME
- ------------------- ----------------------------------------------------------
99.1 Press Release of Abgenix regarding the sole ownership of
XenoMouse fully human antibody.